The $32 Billion Drug That Just Got Its First Real Challenger

The Data Behind FYB206

Formycon and Zydus didn't just walk into the FDA's office and ask nicely. FYB206 went through a pivotal clinical study called DAHLIA, a randomized, double-blind, multicenter trial that demonstrated pharmacokinetic equivalence to Keytruda. In plain English: the drug gets into your body and behaves the same way the original does.

The analytical comparability work (basically a molecular side-by-side comparison) found FYB206 to be highly similar to Keytruda, with only minor physicochemical differences that were judged not clinically relevant. Interestingly, Formycon originally planned a second trial called LOTUS to test efficacy in lung cancer patients, but regulators agreed it wasn't necessary. That's a meaningful signal; the FDA essentially said the existing data package was strong enough to skip an expensive Phase III efficacy study.

A Very Crowded Starting Line

FYB206 may be first to reach FDA review, but it won't be alone for long. The Keytruda biosimilar race has attracted a who's-who of biosimilar heavyweights:

• Samsung Bioepis (SB27): reported meeting primary endpoints in comparability studies and has filed in South Korea.
• Celltrion (CT-P51): in global Phase III development with a Korean filing reported in 2026.
• Amgen: clinical trials reportedly complete, with a U.S. filing expected later in 2026.
• Sandoz, Alvotech/Dr. Reddy's, Bio-Thera, and Qilu Pharmaceutical all have active programs at various stages.

By most counts, at least a dozen companies are chasing a Keytruda biosimilar. That level of competition isn't surprising when you consider the prize: a slice of a drug franchise that generated $16.4 billion in the first half of 2026 alone.

Merck's Patent Fortress

Before biosimilar bulls pop the champagne, there's a massive asterisk here. Merck has built an extensive patent portfolio around Keytruda, and the company has every incentive (read: $30+ billion per year in incentive) to defend it aggressively.

One U.S. Senate letter cited analyst expectations that IV Keytruda biosimilar competition could be delayed until 2036 because of Merck's patent strategy and litigation playbook. That's the Humira model: AbbVie famously used a wall of patents to delay biosimilar competition in the U.S. for years, even as European patients already had access to cheaper alternatives.

The practical biosimilar launch window, based on current reporting, appears to be late 2020s to around 2030, depending on how patent battles shake out. Getting FDA approval is one thing; getting to market is another game entirely.

Why This Matters Beyond Wall Street

The financial stakes are obvious, but the human stakes might be even bigger. Keytruda has become a backbone of modern oncology. And it's expensive enough that access remains a real barrier, particularly in lower-income countries.

The real-world evidence is compelling. When a Keytruda biosimilar launched in Argentina, the government's price offer dropped by 56%, and government purchases surged by more than 1,300%. More patients got treated because the drug got cheaper. That's the biosimilar promise in action.

In the U.S., the numbers are even more striking. Health benefits company Evernorth estimated that delays in biosimilar access could cost commercially insured Americans up to $45.3 billion in lost savings. Every year that biosimilars are kept off the market is a year that patients and payers absorb the full branded price.

The Bottom Line

FYB206's acceptance for FDA review is a milestone, not a finish line. Formycon and Zydus are first through the door, but a dozen competitors are right behind them, and Merck's patent lawyers are standing in the hallway.

Still, the significance is hard to overstate. This is the beginning of the end of Keytruda's monopoly, even if the end itself is still years away. For Merck, the clock is now officially ticking. For cancer patients worldwide, the promise is straightforward: the same life-saving treatment, eventually at a fraction of the cost.

The biggest drug in the world just got its first real challenger. The next 12 months will tell us how seriously to take it.

Novartis Just Bet $7.8 Billion That Your Body Can Build Its Own Medicine

Novartis just paid $575 million upfront for access to Abogen's RNA technology, in a deal worth up to $7.8 billion. The bet: that your own cells can be programmed to build medicines from scratch, starting with a clever new approach to autoimmune disease.